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Dementia is a syndrome that occurs due to the difficulty of a 
patient in doing his cognitive and instrumental activities of daily 
life with the same performance as before, bringing him losses. 
This syndrome is caused by numerous primary and secondary 
etiologies. The most common primary cause of dementia is Alz-
heimer’s disease (AD), which reaches almost 50% of dementia 
cases. The DA it consists of biological fragments of the amyloid 
precursor protein that are deposited in the brain 10 years or 
more, before the first symptoms appear. The period before the 
onset of symptoms is called the preclinical stage. The transition 
between the silence of symptoms and their appearance, usually 
due to memory loss for recent events, is known as the prodromal 
phase. Continuing the pathophysiological process, the stage of 
mild dementia takes place, when the patient has one more cog-
nitive component associated with memory loss; follows the mod-
erate, severe, profound and terminal phase of dementia.
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DEFINITION & GENERALITIES 
Major cognitive disorder 
This criterion was developed by DSM-5, for 
cases that do not characterize neurodegenera-
tive disease40. A - Evidence of significant cogni-
tive decline from a previous level of performance 
in one or more cognitive components - complex 
attention, executive function, learning and 
memory, language, perceptual-motor or social 
cognition. A.1 - Complaint by the individual, in-
formant or clinician with significant decline in ex-
ecutive function. A.2 - Substantial impairment in 
cognitive performance, preferably documented 
by standardized cognitive assessment or in its 
absence by another quantitative assessment. B 
- Cognitive deficits interfere in daily activities - at 
least they require assistance with complex in-
strumental activities of daily life, such as paying 
bills or handling medications. C - Cognitive defi-
cits do not occur exclusively in the context of de-
lirium. D - Cognitive deficits are no longer ex-
plained by another mental disorder such as 
schizophrenia or major depression. 
Dementia is a syndrome characterized by recent 
memory loss and, at least, one more cognitive 
component that causes impairment in activities 
of daily living, for a minimum period of 6 months. 
Dementia can start before age 65, called pre-se-
nile, or after age 65, celled senile. In general, 
most of the pre-senile dementias present with a 
greater intensity of symptoms (BRITO-
MARQUES, 2006)1,2. 
AD can be divided into typical and atypical. Typ-
ical forms are presented in two ways regarding 
evolution: (1) The typical form by progressive an-
terograde amnesia (PAA), with damage to the 
neurons of the hippocampus, especially the 
CA1, CA3 and the dentate gyrus regions. It com-
promises the brain's neural networks of attention 
and the formation of memory, where the patient 
does not learn and becomes progressively rest-
less; and (2) the typical form of forgetfulness de-
clines memory, but maintains lucidity and, pro-
gressively, other cognitive components depend-
ent on memory loss appear. A typical form of 
AAP is always decreasing the degree of 
memory, which can be noticed by a decline in 
the mini-mental state examination (MSE) be-
tween 1 to 3 points per year, while a typical form 
of forgetfulness, keeping the MSE result almost 
unchanged by year. However, a group of pa-
tients of the latter form, with apolipoprotein-E 
(APO-E) ε4 allele, starting at a given point in the 
course of the disease, begins to decline progres-
sively the same as another form (BRITO-
MARQUES, 2001)3. 
Atypical forms of AD are not common and 
memory loss is not the center of the clinical pic-
ture. We will mention some forms: 1) variant of 
progressive aphasic - speech is not fluent, rich 
in neologisms and jargon, there are anomies and 
paraphasias; 2) logopenic progressive aphasia - 
its clinical characteristic is the loss of repetition 
of sentences, search for words in spontaneous 
and confrontational speech, phonological errors 
in spontaneous speech and naming; 3) visospa-
tial variant - patient gets lost in familiar places, 
has difficulty dressing, prosopagnosia, acinetop-
sia, does not recognize objects, visual hallucina-
tions; 4) frontal variant - behavioral disorder with 
progressive apathy, loss of spontaneity, loss of 
empathy, alien hand phenomenon; 5) temporal 
encephalopathy - anxiety disorder accompanied 
by unexplained fear, followed by loss of memory 
and, finally, behavior change; 6) senile dementia 
type tangles - shows behavioral disorder, loss of 
old memory, delusions; 7) senility with high 
schooling - lack of cognitive flexibility, slowness 
in thinking, important occasional memory loss 
(BRITO-MARQUES, 2018)4. 
EPIDEMIOLOGY 
Primary care for the elderly in health posts still 
needs a more directed policy to serve this group 
of patients who depend on a diagnosis with diffi-
cult access to third-party hospitals and, conse-
quently, a trip to the State Pharmacy to receive 
their medication. In most cases, memory loss is 
the most common complaint, since the acquisi-
tion of new information is limited to data of per-
sonal interest already acquired. The retention 
capacity of the new one decreases significantly, 
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from the third and, mainly, from the fourth dec-
ade. So, do not incorporate new technology, no 
thoughts and no mental strategies, being less 
apt to learn new aspects of a world seething that 
every day becomes more distant. The present 
gradually becomes part of the past, and the el-
derly come back to remember episodes making 
them a pleasurable gift or not, declining their 
functional capacity. This physiological change is 
compensated for a long time in people who have 
a good intellectual level to learn new data in their 
time, stimulating their cognition to suit their per-
sonal interest (BRITO-MARQUES, 2006)2. 
The cases of dementia reached 11 million in 
1980, 31 million in 2000 and 35 million in 2010 
worldwide, and if nothing is done to control it, the 
expectation for 2030 will be 65 million and, for 
2050, 115 million. The main reason for this ex-
plosion of prevalence in dementia is the aging of 
the population (ADI, 2009)5. In 2006, 500 million 
people (8% of the world population) were over 
65; for 2030, 13% of the total population is ex-
pected to be over 65 years of age. In developing 
countries, such as Brazil, there is a rapid and 
dramatic expansion of the elderly, with an in-
crease of 141% when compared to only 51% of 
developed countries. And the fastest growth is 
reserved for those 85 years of age or older; for 
this population group, an increase in the range 
of 151% is expected between 2005 and 2030 
(NIA, 2007)6. 
To obtain accurate estimates of the prevalence 
of memory impairment associated with age, de-
mentia and AD, a population-based study was 
carried out in Turegano, a rural community of 
1,011 inhabitants in the province of Segovia, 
Spain. The study was divided into two phases: a 
door-to-door survey of the entire population 
aged 40 or over (503 people), followed by a clin-
ical examination of suspected cases for positive 
and differential diagnosis of dementia and cog-
nitive impairment. The prevalence of age-asso-
ciated memory was 3 to 6% in individuals aged 
40 and over and 7.1% in individuals aged 65 and 
over, while dementia was found in 2-6% and 5-
2%, respectively. The prevalence rates of both 
clinical conditions increased with age. The most 
prevalent clinical category of dementia was Alz-
heimer's, which represented 1-8% and 3-8% of 
these two age groups. The corresponding val-
ues for vascular dementia were 0.4% and 0.90% 
and for secondary dementia 0.44% and 0.5%. 
The memory impairment associated with age is 
an age-dependent disorder, with high preva-
lence among the elderly; some of these patients 
may represent an early stage of AD, suggesting 
that the prevalence of this disorder may be 
higher than previously estimated (CORIA et al., 
1993)7. 
A study carried out in Europe, indicated that Eu-
ropeans are well aware of the potentially devas-
tating consequences of AD, but few are familiar 
with the symptoms of the initial phase. Most 
members of the general population accept that 
early intervention and therapy are essential to 
delay the effects of the disease. Caregivers often 
delayed consulting a doctor about a loved one's 
behavior, in part because of uncertainty about 
the early signs of AD. They also expressed 
doubts about the doctors' ability to make the di-
agnosis. They experience profound effects of 
AD in all areas of their lives - emotional, physical, 
social and financial. People with AD responded 
to their diagnosis in three ways: a fatalistic atti-
tude, a belief that their problems are linked to old 
age or lack of acceptance. Respondents from 
three populations were critical of the level of gov-
ernment investment and support for AD (RIM-
MER et al., 2005)8. 
CLASSIFICATION OF DEMENTIA 
Dementias can be divided into different catego-
ries: by cause - degenerative and non-degener-
ative; location - cortical and subcortical; age of 
onset - early before age 65 and late after age 65; 
treatment - treatable and non-treatable; and evo-
lution - rapidly or slowly progressive. Among de-
mentias, AD is the most common cause, reach-
ing the diagnosis of certainty with 50% of all 
cases of dementia. After 31 years of studying de-
mentias, the pathological diagnosis was con-
firmed in 102 cases followed up since the clinical 
diagnosis. The distribution of etiologies were: 
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49% Alzheimer's disease, 17% cerebrovascular 
disease, 8% Infection, 5% Parkinson's disease, 
4% Brain tumor, 3% Pick's disease, 3% amyo-
trophic lateral sclerosis, 2% Lewy disease, 2% 
Nonspecific, and 9% Collection of basal cortical 
degeneration, Machado-Joseph disease, Hun-
tington's disease, Steiner's bodies, Epilepsy, 
Progressive Supranuclear Palsy, Meningeal car-
cinomatosis, Adrenoleukodystrophy (Figure.1). 
 
 
 
Figure1. Autopsies in 102 cases of dementia 
 
RISK FACTORS 
Risk factors for AD are quite large, since a 
chronic oxidative stress with hippocampal vol-
ume loss by a genetic determination autosomal 
dominant. The most common risk factors are 
age - aging, genetic - first degree relative and 
predisposition, head trauma - loss of conscious-
ness, and depression - after 50 years. 
Aging 
Aging is considered the greatest risk factor for 
AD: the older you are, the greater the risk of de-
veloping it. Studies show that the incidence of 
dementia doubles approximately every 5-6 
years, between the ages of 65 and 90 years 
(ZIEGLER-GRAHAM, 2008)9. The incidence of 
all causes of dementia is very high in people 
aged 90 and older, 41% per year, and continues 
to increase exponentially with age in both sexes. 
Projections for the number of people with de-
mentia should be incorporated into this continu-
ing increase in dementia after age 90. These 
data predict the growing burden of dementia on 
public health in an increasingly aging and under-
served population (CORRADA et al., 2010)10. 
Genetic aspects 
The so-called familial genetic form corresponds 
to 3 to 5% of AD cases and the rest are sporadic 
forms. Early onset Alzheimer's disease (EOAD) 
begins before age 50, sometimes as early that 
arises in the decade of 20 years and has a 
strong genetic connotation. Three chromosomes 
are part of EOAD. Chromosome-14 and 1, are 
responsible for mutations of presenilins-14 and 
1, and chromosome-21, for the amyloid precur-
sor protein; are autosomal dominant forms of AD 
In contrast, late-onset Alzheimer's disease 
(LOAD) has an increased risk relationship with 
first-degree relatives who also had the same dis-
ease, although it is not an established genetic 
cause. On chromosome-19 there is the gene 
that transcribes apolipoprotein-E (APO-E), 
which is presented by the ε2, ε3 and ε4 allele; 
the ε4 allele is considered a risk factor and the 
ε2 allele as a protective factor for LOAD. When 
the patient has the heterozygous form, ε3/ε4, his 
risk of developing DAIT increases up to 5 times, 
when he has the homozygous form, ε4 / ε4, the 
risk can reach up to 15 times (SCHU et al., 
2012)11. 
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Head trauma 
Head trauma (HT) is the third leading cause of 
dementia in people over 60 years old, especially 
in athletes and soldiers. One study showed that 
a severe head injury resulted in the deposition of 
beta-amyloid protein (βA) in the cortex of 30% of 
patients who survived for less than two weeks. 
Multiple cortical areas were examined from 152 
patients (age range 8 weeks to 81 years) after 
severe traumatic brain injury with a survival time 
between four hours and 25 years. This series 
was compared with a group of 44 neurologically 
normal controls (age range 51 to 80 years In-
creasing age appeared to accentuate the extent 
of βA deposition and potential correlations with 
other pathological changes associated with HT 
were also investigated. The data in this study 
support that the increase in βA expression is part 
of an acute phase of HT in response to neuronal 
damage in the human brain, this increase in βA 
may lead to its progressive deposition to Alzhei-
mer's pathology, and HT may be an important 
etiological factor in Alzheimer's disease (ROB-
ERTS et al., 1994)12. 
Depression 
Depression has been identified as a risk factor 
for AD. People with a history of depression are 
2.5 times more likely to develop AD than people 
who have never had depression, this association 
being independent of the incidence of vascular 
risk factor and stroke. Those who have late-on-
set depression, after 60, but not depressive 
symptoms, are especially vulnerable to AD, with 
a 4-fold increased risk, regardless of the volume 
of the amygdala or the hippocampus (GEER-
LINGS et al., 2008)13. Patients with a family his-
tory of depression or who started early in adult-
hood, should generally not be considered as a 
risk factor for AD. It is not uncommon, in patients 
with mild AD, to be reported in the history, that 
before the memory loss had one or more epi-
sodes of depression, treatment was done, im-
proved, but then the progressive memory loss 
appeared. 
CRITERIA FOR DIAGNOSIS OF DEMENTIA 
OF ANY ETIOLOGY 
In dementia there should be no deficit in any of 
the 5 senses, nor motor. 1. Dementia is diag-
nosed when there are cognitive or behavioral 
symptoms that: 1.1. They interfere with tasks, 
work or daily activities. 1.2. They represent a de-
cline from previous levels of functioning and per-
formance. 1.3. They cannot be explained by de-
lirium, confusion or psychiatric illness. 2. Cogni-
tive impairment is diagnosed by combining: 2.1. 
Anamnesis with the patient, and an informant 
who has knowledge of the history. 2.2. Objective 
cognitive assessment with the mini-mental state 
examination; Comprehensive cognitive assess-
ment should only be performed when neces-
sary.3. The cognitive or behavioral components 
affect at least two of the following components: 
3.1. Memory, with inability to learn and recall re-
cent information; repetitions of questions or sub-
jects, forgetting events, where they kept their be-
longings. 3.2. Executive dysfunctions (plan, al-
ternate and execute); affect understanding, 
judgment, taking care of finances and making 
decisions. 3.3. Visospatial difficulties due to ag-
nosia for objects and face, optical apraxia, diffi-
culty in handling utensils, dressing. 3.4. Lan-
guage dysfunction (expression, comprehension, 
reading and writing), difficulty in finding or under-
standing words, and anomie. 3.5. Personality or 
behavior altered by mood (lability and fluctua-
tions), agitation, apathy, disinterest, social isola-
tion, loss of empathy, disinhibition, obsessive, 
compulsive or socially unacceptable behaviors 
(McKhann et al., 2011)14. 
CRITERIA FOR DIAGNOSIS OF ALZHEI-
MER'S DISEASE 
The definition of AD criteria has been going on 
for more than 2 decades. In the beginning, AD 
was considered only a pathological disease. 
From 2007, AD started to be considered a path-
ophysiological continuum between the pre-
symptomatic, prodromal and dementia phase 
(Dubois et al. 2007; Dubois et al. 2010) 15 , 16 . 
These criteria described by Bruno Dubois and 
team for AD are one of the most complete car-
ried out in recent years, they correspond to a sci-
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entific research very well elaborated and exe-
cuted, however it is not a static model, it serves 
as a diagnostic guide lived together with the ex-
perience examiner. Other criteria were also pub-
lished for AD (McKhann et al., 2011; KNOPMAN 
et al, 2018)14,17. 
Alzheimer's disease 
AD is a diagnostic label that is restricted to the 
clinical disorder that begins with the first specific 
symptoms of the disease and encompasses 
both pre-dementia and dementia. AD refers to 
the entire spectrum of the clinical phase of the 
disease and is not restricted to dementia syn-
drome. The diagnosis is now established in vivo 
and is based on a double clinical-biological entity 
that requires evidence of specific memory 
changes and in vivo markers of AD. The pathol-
ogy includes, in the CSF, a reduction in the lev-
els of amyloid protein, and an increase in total 
tau protein and tau phosphorylated protein; the 
retention of specific amyloid tracers in the PET-
scan exam; atrophy of the medial temporal lobe 
at MRI; and / or temporal / parietal hypometabo-
lism on PET-scan with fluorodeoxyglucose. The 
clinical phenotype can be typical or atypical. In 
addition, two different clinical stages can still be 
significant: a prodromal phase and a dementia 
phase. 
Prodrome of Alzheimer's disease or “pre-de-
mentia phase in AD” 
This term refers to the early symptomatic phase 
of AD in which (1) clinical symptom, including ep-
isodic memory loss of the hippocampal type, 
characterized by deficit of free recall in non-nor-
malized tests with clue, but are not severe 
enough to affect activities that are instrumental 
in daily life and do not justify a diagnosis of de-
mentia; and (2) evidence of CSF or image bi-
omarkers supports the presence of pathological 
changes in AD. This phase is now included in the 
new definition of AD. The term prodromal AD 
may disappear in the future if AD is considered 
to encompass the stages of pre-dementia and 
dementia. 
Dementia in Alzheimer's disease 
This term refers to the AD phase during which 
cognitive symptoms are severe enough to inter-
fere with social functioning and instrumental ac-
tivities of daily living, a threshold considered as 
a determinant of dementia associated with 
changes in episodic memory and at least one 
other cognitive component. It may also be signif-
icant to identify the dementia threshold for clini-
cal trials or socioeconomic assessments. 
Typical Alzheimer's disease 
This term refers to the most common clinical 
phenotype of AD, characterized by an early and 
progressive episodic memory deficit, which re-
mains dominant in the more advanced stages of 
the disease, being followed or associated with 
other cognitive changes, such as executive func-
tions, language, praxis and complex visospatial 
deficits, and neuropsychiatric disorders. The di-
agnosis is further supported by one or more life-
positive biomarkers of Alzheimer's disease. 
Atypical Alzheimer's disease 
This term refers to the less common and well-
characterized clinical phenotypes of the disease 
that occur with Alzheimer's disease. These clini-
cal syndromes include progressive non-fluent 
primary aphasia, logopenic aphasia, frontal var-
iant of AD and posterior cortical atrophy. In the 
presence of one of these clinical representa-
tions, the diagnosis of AD is supported by living 
evidence of amyloid protein deposited in the 
brain using PET-scan or CSF, with changes in 
the concentration of βA protein, tau-protein and 
tau-phosphorylated. 
Mixed Alzheimer's disease 
This term refers to patients who fully meet the 
diagnostic criteria for typical AD and, in addition, 
present clinical and biological brain imaging evi-
dence of other disorders such as cerebrovascu-
lar disease or Lewy body disease. 
Preclinical states of Alzheimer's disease 
These terms refer to the asymptomatic phase 
since the oldest pathogenic events of AD brain 
lesions, and the first appearance of specific cog-
nitive symptoms. A preclinical or asymptomatic 
phase was recognized post-mortem by evidence 
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of histological changes typical of Alzheimer's pa-
thology in individuals considered to be cogni-
tively normal in life. Currently, two preclinical 
stages can be isolated in life: (1) Asymptomatic 
risk stage for AD - this stage can be identified in 
vivo by evidence of amyloid in the brain, with re-
tention of specific markers on amyloid PET-scan 
or CSF examination with changes in β-amyloid 
protein concentrations, phosphorylated tau and 
tau. In the absence of knowledge about the 
value of these biological changes to predict dis-
ease development, the asymptomatic phase of 
AD is still referred to as a “risk stage for AD”. (2) 
Pre-symptomatic stage of AD - this stage applies 
to individuals who will develop AD. This can only 
be determined in families that are rarely affected 
by autosomal dominant monogenic mutations 
(monogenic Alzheimer's disease). 
Alzheimer's pathology 
This term refers to the underlying neurobiologi-
cal changes responsible for AD that encompass 
the earliest pathogenic events in the brain and 
that include specific neuronal brain injuries, neu-
ritic plaques, senile and neurofibrillary tangles, 
synaptic loss and vascular amyloid deposits 
within the cerebral cortex. This term can be ap-
plied regardless of the existence of a clinical 
manifestation. 
Mild cognitive impairment 
This term applies to individuals with measurable 
mild cognitive impairment (CCL) in the absence 
of a significant effect on instrumental activities of 
daily living. This diagnostic label is applied if 
there is no disease to which the CCL can be as-
signed. It continues to be an exclusion term for 
individuals who are suspected of having it, but 
do not meet the new research criteria proposed 
for AD, as they deviate from the clinical-biologi-
cal phenotype of prodromal AD because they 
have memory symptoms that they are not char-
acteristic of AD, or because they are negative bi-
omarkers. 
COGNITIVE EVALUATION 
Assessing a patient with possible AD is more 
than a cognitive task. It is a disease in which the 
patient does not recognize himself in a mirror, he 
loses the notion of extrapersonal space and his 
peripheral self when mentioning how he, in this 
way, is facing a disease without a soul. The eval-
uation presents two moments of investigation 
using: (1) subjective instruments, and (2) objec-
tive instruments. The subjective instruments are 
the most important, which acquire patterns of 
clinical behavior proportional to the experience 
of the examiner. The objective instruments work 
as a complementary exam, which must have a 
direct connection with the data obtained in the 
subjective investigation (BRITO-MARQUES, 
1999)18. 
The first subjective instrument is the medical his-
tory that can reach the possibility of 60% of the 
clinical diagnosis, especially when it comes to 
neurodegenerative diseases. The story requires 
both specialized medical training and a human-
istic perception of the patient and his family, in 
knowing that the other is also part of you as a 
distorted mirror image. The patient is vulnerable, 
even if he is not aware of his suffering, therefore, 
the doctor must welcome him at his best. The 
development of this humanistic sense gives the 
doctor a closer relationship with his patient, con-
solidating the cornerstone of medicine - the doc-
tor-patient relationship. 
The second subjective instrument is the 
knowledge of neurophysiology of the cerebral 
cortex applied to the clinic. Emphasize, at least, 
how the five neural networks of the cerebral cor-
tex work as a prerequisite for the early diagnosis 
of AD. Neural networks are at association levels 
using tertiary and quaternary brain areas, 
through attention, memory, language, visospa-
tial and executive. (1) Dominant spatial attention 
network in the right cerebral hemisphere, with 
the posterior parietal cortex, frontal field of the 
eyes and the cingulate gyrus as epicenters; (2) 
Dominant language network in the left cerebral 
hemisphere, with epicenters in the areas of Wer-
nicke and Broca; (3) Memory and emotion net-
work with epicenters in the entorhinal, hippo-
campal and tonsillar complex regions; (4) Net-
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work that holds executive functions with epicen-
ters in the lateral prefrontal cortex, orbitofrontal 
and posterior parietal cortex; (5) Object and face 
identification network with epicenters in the lat-
eral temporal cortex and in the temporal pole 
(mesulam, 2000)19. 
The third subjective instrument is the quality of 
the patient's education. In developing countries 
like Brazil, the level of education may not serve 
as a parameter. The patient's school and profes-
sional life, as well as his emotional family situa-
tion are factors of great impact in the diagnosis 
process. In a cross-sectional study, people be-
tween 60 and 90 years were studied, whose illit-
erates differed from individuals with 5 years of 
schooling (BRITO-MARQUES, CABRAL-
FILHO, 2003; BRITO-MARQUES, CABRAL-
FILHO, 2004)20,21. 
The first objective instrument is the mini-mental 
state examination (MSE). It is a clinical screen-
ing test that initiates a cognitive assessment by 
directing the examiner to the most altered cogni-
tive components. This test was first described by 
Folstein et al. (1975)22, to differentiate psychiat-
ric and neurological patients with schooling from 
8 years old. In Brazil, the MSE was adapted in 
1994 by Bertolucci et al.23, Studying patients be-
tween 15 and 65 years of age or older, showing 
the great impact that had on education. In 1999, 
Brito-Marques, changed the MSE to the mini-
mental state exam according to schooling 
(MSEAS). He studied patients between 60 and 
92 years of age, living in a community (BRITO-
MARQUES, 1999)24,25. 
The MSE is a screening tool, the score ranges 
from 0 to 30, divided into temporal and spatial 
orientation, immediate memory, evocation, lan-
guage and praxis. The cutoff point is variable, 
between 24 to 26 points, in the State of Pernam-
buco 24 is accepted. The MSE when used for 
diagnostic purposes, has several limitations, es-
pecially with individuals with high education. 
These elderly individuals may have MSE above 
26 points and, even so, be in the prodrome or 
mild dementia stage. Returning to the neural net-
works, it can be observed in the conversation 
with these patients, with MSE above 26 points, 
a greater difficulty in understanding, an easy 
smile and not fixing new information, which are 
incompatible data that the high score (BRITO-
MARQUES, CABRAL-FILHO, 2005)26,27. 
Assessment of mood in Alzheimer's demen-
tia 
Humor is the fuel that provides conditions for the 
balance of brain functioning. It is from this bal-
ance, more or less, that cognition feeds a behav-
ior such as: pleasant or unpleasant. The assess-
ment of mood must be carried out in all patients 
over 60 years of age who are experiencing some 
difficulty in their family or professional life, di-
rectly affecting the cognitive. The elderly go be-
yond a stage of life when they feel vulnerable 
more easily than in previous times. Monitoring 
the mood of the elderly patient along with the 
evolution of a cognitive decline may show more 
clarity in the cognitive diagnosis. The geriatric 
depression scale is a useful tool for assessing 
patients with dementia and mood disorders. The 
scale has 30 items with YES and NO responses 
(YESAVAGE et al. 1983)28. The Brazilian ver-
sion of the geriatric depression scale was re-
duced to 15 items (PARADELA et al. 2005)29. 
Functional assessment 
The functional fragmentation of the elderly is 
less influenced than that of cognition when they 
have little schooling, vice versa. In people with 
little schooling, the automation of functional 
tasks is organized in motor programs, formed on 
a daily basis during the life of each person and, 
when elderly, the losses of little cognition in-
crease and give way to functionality. 
In practice, a fast and reliable instrument is 
needed to detect the presence of intellectual dis-
ability and the degree. A short Mental State 
Questionnaire, containing 10 items, easily ad-
ministered by any clinician in the office or in a 
hospital, was designed, tested, standardized 
and validated. It was found that educational level 
and race had to be taken into account when 
scoring individual performance. Based on the 
large population of the community, performance 
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standards have been established for: 1) intact 
mental functioning, 2) borderline or mild organic 
impairment, 3) defined but moderate organic im-
pairment, and 4) severe organic impairment. 
There was a high level of agreement between 
the clinical diagnosis of organic brain syndrome 
and the scores in the Pfeiffer Functional Activity 
Questionnaire (FAQ), which indicated moderate 
or severe organic impairment. Up to five points, 
the Pfeiffer questionnaire is acceptable as nor-
mal (PFEIFFER, 1975)30. 
COMPLEMENTARY EXAMS 
Alzheimer's disease cannot be diagnosed by 
any additional exam. However, specific blood 
rates must be performed to rule out other morbid 
conditions. For example, examining vitamin B12, 
homocysteine, folic acid and CBC can lead to 
another diagnosis. The blood rate of altered ho-
mocysteine should be corrected as a factor as-
sociated with the evolution of AD and other de-
mentias, such as vascular dementia. The blood 
rate of VDRL and FTA-abs can show syphilis, 
which can facilitate the diagnosis of dementia. 
The altered rate of thyroid hormones may be rel-
evant in the diagnosis of dementia. The low rate 
of chronic sodium may justify the altered level of 
consciousness and, consequently, dysfunction 
of the content of consciousness. 
The glycemia rate, even in non-diabetic individ-
uals, is important in the rare cases of insulinoma, 
evolving with fluctuating hypoglycemia, deterio-
ration of cognition and dementia. Type III diabe-
tes is one of the causes of AD, although this bi-
ological marker does not yet exist in Brazil. 
Blood tests showing abnormal levels of creati-
nine and / or urea, such as liver function rates, 
can direct the diagnosis in another direction. The 
tests for dyslipidemia, total cholesterol, fractions 
and triglycerides are not of great relevance for 
the diagnosis of AD. However, there is a clinical 
form of AD that evolves slowly with changes in 
cholesterol, which is why, for a long time, it was 
believed that cognitive changes are caused by 
increased levels of cholesterol in the blood. Rou-
tine is thyroid, renal, hepatic function; blood 
count, ionogram, blood glucose, VDRL and vita-
min-B12. 
Neuroimaging exam 
Neuroimaging is used in the diagnosis of demen-
tia, especially Alzheimer's disease (AD). Com-
puted tomography (CT) can be used to exclude 
other causes of dementia than AD. The finding 
of cortical or subcortical atrophy on CT or mag-
netic resonance imaging (MRI) itself does not in-
dicate AD. Atrophy of the hippocampus on CT / 
MRI provides a useful early marker, although a 
longitudinal and neuropathological study is 
needed. CT and MRI-based measurements of 
hippocampal atrophy are promising in providing 
useful diagnostic information to discriminate pa-
tients with probable AD from normal elderly. The 
use of a standardized imaging protocol, includ-
ing some assessment of hippocampal atrophy, 
can reduce costs, as patients with suspected AD 
should undergo a cross-sectional imaging study 
to exclude other (treatable) causes of dementia. 
The combination of an assessment of hippocam-
pal atrophy with measurements of cerebral 
blood flow by single-photon emission computed 
tomography is not justified clinically or economi-
cally. MRI examination of the skull may show 
specific changes in atrophy between the cere-
bral cortex and the hippocampus. The cerebral 
cortex shows atrophy expected for age, while the 
hippocampus shows atrophy in an advanced de-
gree for age, according to an MTA scale. Schel-
tens showed that in MRI of the skull, in coronal 
section, it shows 4 degrees of atrophy; up to 75 
years old, the 2 degree atrophy score will be ac-
cepted as normal. Score 0: no atrophy. Score 1: 
only widening of the choroidal fissure. Score 2: 
widening of the choroidal fissure and temporal 
horn of the lateral ventricle. Score 3: moderate 
loss of hippocampal volume (reduced height). 
Score 4: severe loss of hippocampal volume 
(SCHELTENS, 1999)31.  
Examination of the cerebrospinal fluid 
CSF testing is generally used for patients with 
cancer, suspected neuroinfection, positive 
VDRL and FTA-abs in the blood, but should be 
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used in patients under 55 years of age, including 
those with MCI. In the NINCDS-ADRDA guide-
lines, the CSF examination was recommended 
as a non-Alzheimer's dementia exclusion pro-
cess, due to inflammatory vasculitis, demyelinat-
ing disease or secondary demyelination, etc. In 
the last decade, the MCI's request to observe the 
concentration of biomarkers, including their con-
centration by age group, has been growing. The 
biological markers in CSF for AD include (βA-
42), phosphorylated tau protein (tau-181 and 
tau- 231) and total tau protein (tau-t). 
In AD, βA-42 protein levels are inversely related 
to the number of amyloid plaques, total tau pro-
tein levels represent the intensity of neuronal de-
generation and are increased, and levels of tau 
phosphorylated protein indicate the intensity of 
neurofibrillary degeneration, which are in-
creased. Therefore, the concentration of Aβ-42 
in the CSF is low, and that of the protein tau-t 
and tau-f high, compared with controls. CSF Aβ-
42 protein levels are about 50% lower in AD pa-
tients than in controls of the same age group. 
The levels of tau protein do not correlate with the 
MSE score. The tau protein is increased in most 
patients at an early stage of AD, and can be 
used as a support in their diagnosis. The con-
centrations of different epithets of the tau-f pro-
tein can also be high, the most specific for DA 
(GALASKO, 1997; SKILLABACK et al., 
2015)32,33. 
TREATMENT IN ALZHEIMER'S DEMENTIA 
To date, AD has no cure, but it has treatment. 
Non-pharmacological treatment emerges as a 
promising attempt for the prodromal phase of 
AD, when there is still no anticholinesterase re-
sponse. For the mild to moderate dementia 
phase, donepezil, rivastigmine and galantamine 
are used, and in the moderately-severe to se-
vere phase, NMDA receptor inhibitors are asso-
ciated. In the next 5 years, we will have a new 
treatment, anti-beta-amyloid, to be used in the 
prodromal and mild phase of Alzheimer's de-
mentia. 
Non-pharmacological treatment 
Accumulated evidence has shown that nutri-
tional factors influence the risk of developing AD 
and its rate of clinical progression. Loss of epi-
sodic memory and insight are clinical manifesta-
tions of the prodromal phase of AD, not yet no-
ticed in objective assessments. This is the first 
time that a randomized, double-blind clinical trial 
using Souvenaid has shown that a nutritional in-
tervention can help conserve the ability of pa-
tients with prodromal AD to perform everyday 
tasks, such as paying bills or finding their way 
back. This is important because patients with 
prodromal AD currently do not have available 
and approved pharmacological options. The 
study found no significant benefit in broad cogni-
tive function. The cognitive decline during the 
study period was less than originally expected 
when it was designed ten years ago, so the dif-
ferences found between the two groups were too 
small to be statistically significant due to the size 
of their samples (SOININEM et al., 2017)34. 
Pharmacological treatment 
Donepezil is a highly specific, reversible cholin-
esterase inhibitor. Piperidine-based molecule 
without hepatotoxic effect with linear pharmaco-
kinetics and long life, which can be administered 
once daily at a dose of 5 mg / day or 10 mg / day. 
The dose can be increased for patients in the 
moderate to severe phase up to 23 mg \ day, as 
long as they have used a dose of 10 mg per day 
for at least 3 months without intolerance. The 
dosage of donepezil is 5 mg daily, orally, for 45 
days; followed by the 10mg dose, always at the 
same time after a meal. If after dinner, the pa-
tient favors himself with mild drowsiness. Side 
effects are nausea, diarrhea, abdominal discom-
fort, headache, insomnia, fatigue and night-
mares, disappearing with drug suspension or 
dose reduction (WANG et al., 2010)35. 
Rivastigmine is a selective and pseudo-reversi-
ble inhibitor of acetylcholinesterase and butyryl-
cholinesterase. The oral dosage should be 
started at 1.5 mg 12 \ 12 hours and increase to 
3.0 mg 12 \ 12 hours, 4.5 mg 12 \ 12 hours and 
6.0 mg 12 \ 12 hours, right after breakfast and 
dinner. The dose increase should be done every 
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15 or 30 days, depending on the possible side 
effects. Patients have side effects in 20% of 
cases, as the titration of the drug increases, such 
as: nausea, vomiting, dizziness, diarrhea, head-
ache and weight loss, isolated or associated. Ad-
hesive, transdermal rivastigmine, with a dose of 
9 mg \ 24 hours and, after 30 days, 18 mg \ 24 
hours, without gastric effects. This presentation 
helps treatment due to the fact that 73% of AD 
patients need help to take their medication, 22% 
manage to take it without help, and 5% do not 
take it; besides the certainty that the patient is 
using it. The transdermal dosage starts with 5 in 
the first month; 10, in the second, and 15, in the 
third onwards, always reevaluating the possibil-
ity of the presence of side effects (SPIEGEL, 
2002)36. 
Galantamine is a competitive, selective cholin-
esterase inhibitor that also acts on cholinergic 
nicotinic neurotransmitters by modulating nico-
tinic receptors. Oral galantamine-ER begins to 
be taken at a dose of 8 mg in the first month, 16 
mg in the second month, and 24 mg in the third 
month onwards, always after one of the three 
main meals; the therapeutic dose is between 16 
and 24 mg. Side effects include nausea, vomit-
ing, anorexia, weight loss and diarrhea. Studies 
with galantamine have shown their most specific 
action in mixed dementias, those that have vas-
cular pathology associated with Alzheimer's pa-
thology, improving executive and memory alter-
ations (COREY-BLOOM, 2003)37. 
The N-methyl-D-aspartate (NMDA) receptor is a 
glutamate receptor indicated for pathological 
changes in AD. Blocking this receptor can pro-
tect neurons against excitotoxic effects, which 
lead to cell death. Memantine is a non-competi-
tive NMDA receptor antagonist, with mild to 
moderate affinity. It blocks the selection of exci-
totoxic effects associated with abnormal gluta-
mate transmission, while allowing physiological 
transmission related to normal cell function to 
occur.Memantine has been approved by the 
FDA for the treatment of AD in the moderately 
severe to severe phase. It should be adminis-
tered in slowly progressive doses with 5 mg per 
day, for a week and increase 5 mg every week, 
until reaching the therapeutic dose of 10 mg for 
12 \ 12 hours or 20 mg / day. Its immediate, most 
common side effects are: dizziness, headache, 
constipation and confusion (REISBERG et al., 
2003)38. 
Antidepressant treatment 
Every patient with AD who presents depressive 
symptoms should start pharmacological treat-
ment. Serotonin reuptake inhibitors are im-
portant in memory formation at a very early bio-
chemical stage. The starting dose of the drug de-
pends on the personality profile brought by the 
patient, especially if he is aware of his pathology. 
In a more advanced, moderate to severe phase, 
the patient should use trazodone as the first op-
tion, for cases of self-destruction, which starts as 
subtle as a tic, scratching the same place or 
touching the hair, until forming wounds and in-
fected alopecia. 
Antipsychotic treatment 
In the moderate phase, the first signs of distor-
tion of thought begin. The personality profile has 
great relevance at this stage. Diplomacy can 
help balance episodes. Pharmacological treat-
ment is necessary in some cases, especially in 
males. The choice is based on the experience of 
each doctor, but in decreasing order: olanzap-
ine, quetiapine and risperidone are the most 
used. Start with a low dose and find out if there 
is a stress factor triggering the crisis. This factor 
can have an emotional or physical basis. The 
emotional is linked to life history, basically fear, 
especially at night. The physical may be dental 
caries, fecaloma, joint pain, muscle strain, etc 
(ROPACKI, JESTE, 2005)39.  
(1) confusion between lived situations, despite 
having existed, time, place or people are ex-
changed, generating a confusion of ideas that, 
unsuspecting caregivers can increase, but co-
herent ideas can be partially rescued with diplo-
matic help, giving the person his reason or sub-
tly, to divert the focus of attention from the con-
versation and change the environment; (2) Illu-
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sions begin with visual doubts, later accompa-
nied by hallucinations. The phenomenon of pro-
sopagnosia is one of the moments of greatest 
emotional conflict for the spouse and relatives 
and, seeing what does not exist, opens the door 
to the next phase. This phase is followed by 
Capgras syndrome, or the double. In this phase, 
there is a functional disconnection of the corpus 
callosum between the language and the viso-
spatial areas, especially when the patient is in 
front of the mirror. The mirrors of the house must 
be removed. 
(3) Delusions are related to the past life that 
works for the patient as a present. He does not 
recognize his spouse, his children or his home, 
and lives as if they were all other people named 
by him, the spouse can be the father or the 
mother, the daughter the sister, etc. Thus, the 
person declines to childhood. There were oppor-
tunities to experience this fact at the Karolinska 
Institute, Stockholm, when people lived in cus-
tom kits for their young adult days; smiling, wel-
coming people as if they were in their own home. 
The 10 most common psychotic symptoms in 
patients with dementia in Alzheimer's disease, 
which occur at least 2 or 3 times a week, are: 1) 
people are stealing from him; 2) his spouse is 
cheating on him; 3) unwelcome guests are living 
in his home; 4) his spouse or other relatives are 
not who they claim to be; 5) his home is not him; 
6) His family members plan to leave him; 7) The 
TV characters are present in his home and inter-
act with him; 8) Talk to people who are not pre-
sent; 9) See people or animals that other people 
don't see; 10) He says he feels things walking on 
his skin. 
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